Natera, Inc. (NTRA)
USD 146.95
(2.56%)
USD 146.95
(2.56%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -200.1 Million USD | -629.63% |
| 2022 | -27.42 Million USD | -108.93% |
| 2021 | 307.09 Million USD | 36.41% |
| 2020 | 225.12 Million USD | 155.39% |
| 2019 | 88.15 Million USD | 14.33% |
| 2018 | 77.1 Million USD | -30.26% |
| 2017 | 110.55 Million USD | 221.69% |
| 2016 | 34.36 Million USD | 161.49% |
| 2015 | 13.14 Million USD | 121.77% |
| 2014 | -60.36 Million USD | -875.31% |
| 2013 | -6.18 Million USD | -7.69% |
| 2012 | -5.74 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -359.19 Million USD | 3.96% |
| 2024 Q1 | -374.02 Million USD | -86.92% |
| 2023 FY | -200.1 Million USD | -629.63% |
| 2023 Q2 | 52.69 Million USD | 59.33% |
| 2023 Q3 | -237.36 Million USD | -550.48% |
| 2023 Q1 | 33.07 Million USD | 267.14% |
| 2023 Q4 | -200.1 Million USD | 15.7% |
| 2022 Q4 | -19.78 Million USD | -105.51% |
| 2022 Q3 | 359.04 Million USD | 15.5% |
| 2022 FY | -27.42 Million USD | -108.93% |
| 2022 Q1 | 245.17 Million USD | -21.63% |
| 2022 Q2 | 310.86 Million USD | 26.79% |
| 2021 FY | 307.09 Million USD | 36.41% |
| 2021 Q1 | 315.2 Million USD | 35.62% |
| 2021 Q2 | 316.53 Million USD | 0.42% |
| 2021 Q3 | 283.41 Million USD | -10.46% |
| 2021 Q4 | 312.84 Million USD | 10.38% |
| 2020 Q4 | 232.42 Million USD | 274.25% |
| 2020 Q2 | 193.32 Million USD | 162.84% |
| 2020 Q1 | 73.55 Million USD | -16.56% |
| 2020 FY | 225.12 Million USD | 155.39% |
| 2020 Q3 | 62.1 Million USD | -67.88% |
| 2019 Q4 | 88.15 Million USD | -11.79% |
| 2019 FY | 88.15 Million USD | 14.33% |
| 2019 Q3 | 99.93 Million USD | -18.76% |
| 2019 Q2 | 123 Million USD | 2.52% |
| 2019 Q1 | 119.97 Million USD | 55.61% |
| 2018 Q4 | 77.1 Million USD | -13.25% |
| 2018 FY | 77.1 Million USD | -30.26% |
| 2018 Q1 | 89.58 Million USD | -18.97% |
| 2018 Q2 | 111.03 Million USD | 23.94% |
| 2018 Q3 | 88.88 Million USD | -19.95% |
| 2017 FY | 110.55 Million USD | 221.69% |
| 2017 Q4 | 110.55 Million USD | -1.37% |
| 2017 Q3 | 112.08 Million USD | 161.37% |
| 2017 Q2 | 42.88 Million USD | 5.31% |
| 2017 Q1 | 40.72 Million USD | 18.49% |
| 2016 Q3 | 24.15 Million USD | -26.3% |
| 2016 Q2 | 32.77 Million USD | 298.66% |
| 2016 Q1 | 8.22 Million USD | -37.46% |
| 2016 Q4 | 34.36 Million USD | 42.3% |
| 2016 FY | 34.36 Million USD | 161.49% |
| 2015 Q4 | 13.14 Million USD | 107.51% |
| 2015 Q3 | -174.91 Million USD | -407.34% |
| 2015 Q2 | -34.47 Million USD | 34.1% |
| 2015 FY | 13.14 Million USD | 121.77% |
| 2015 Q1 | -52.31 Million USD | 13.32% |
| 2014 FY | -60.36 Million USD | -875.31% |
| 2014 Q1 | 2.79 Million USD | 145.21% |
| 2014 Q3 | 249 Thousand USD | 0.0% |
| 2014 Q4 | -60.36 Million USD | -24341.77% |
| 2013 FY | -6.18 Million USD | -7.69% |
| 2013 Q1 | 5.74 Million USD | 0.0% |
| 2013 Q4 | -6.18 Million USD | 0.0% |
| 2012 FY | -5.74 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -39.45 Million USD | -407.204% |
| Applied DNA Sciences, Inc. | -5.91 Million USD | -3283.508% |
| Aspira Women's Health Inc. | -331 Thousand USD | -60353.776% |
| Biodesix, Inc. | 34.3 Million USD | 683.269% |
| BioNexus Gene Lab Corp. | -5.79 Million USD | -3352.451% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | -15999.204% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | -15999.204% |
| Bionano Genomics, Inc. | 34.88 Million USD | 673.654% |
| CareDx, Inc | -47.97 Million USD | -317.088% |
| Check-Cap Ltd. | -24.75 Million USD | -708.297% |
| Castle Biosciences, Inc. | -83.53 Million USD | -139.554% |
| DarioHealth Corp. | -7.54 Million USD | -2551.06% |
| Exact Sciences Corporation | 1.94 Billion USD | 110.265% |
| Fulgent Genetics, Inc. | -82.56 Million USD | -142.354% |
| Guardant Health, Inc. | 220.22 Million USD | 190.862% |
| ICON Public Limited Company | 3.56 Billion USD | 105.62% |
| IDEXX Laboratories, Inc. | 493.94 Million USD | 140.511% |
| Illumina, Inc. | 1.21 Billion USD | 116.483% |
| Intelligent Bio Solutions Inc. | -5.43 Million USD | -3583.317% |
| iSpecimen Inc. | -2.14 Million USD | -9218.243% |
| Standard BioTools Inc. | 46.5 Million USD | 530.271% |
| MDxHealth SA | 18.88 Million USD | 1159.582% |
| 23andMe Holding Co. | -141.37 Million USD | -41.543% |
| Medpace Holdings, Inc. | -103.32 Million USD | -93.659% |
| Myriad Genetics, Inc. | 88.1 Million USD | 327.131% |
| Mainz Biomed B.V. | 349.85 Thousand USD | 57295.695% |
| ENDRA Life Sciences Inc. | -2.43 Million USD | -8102.569% |
| NeoGenomics, Inc. | 269.19 Million USD | 174.335% |
| Neogen Corporation | 735.62 Million USD | 127.202% |
| Inotiv, Inc. | 382.14 Million USD | 152.362% |
| OpGen, Inc. | 11.89 Million USD | 1782.677% |
| OPKO Health, Inc. | 230.68 Million USD | 186.743% |
| Psychemedics Corporation | 334 Thousand USD | 60010.778% |
| Prenetics Global Limited | -43.33 Million USD | -361.734% |
| Prenetics Global Limited | -43.33 Million USD | -361.734% |
| Precipio, Inc. | -386 Thousand USD | -51739.896% |
| Personalis, Inc. | -8.02 Million USD | -2394.415% |
| RadNet, Inc. | 1.14 Billion USD | 117.422% |
| Sera Prognostics, Inc. | -2.02 Million USD | -9796.241% |
| Sotera Health Company | 2.02 Billion USD | 109.88% |
| Neuronetics, Inc. | 2.79 Million USD | 7254.165% |
| Star Equity Holdings, Inc. | -15.33 Million USD | -1204.701% |
| Star Equity Holdings, Inc. | -15.33 Million USD | -1204.701% |
| Trinity Biotech plc | 63.73 Million USD | 413.954% |
| T2 Biosystems, Inc. | 33.8 Million USD | 691.86% |
| Twist Bioscience Corporation | -192.4 Million USD | -4.003% |
| Exagen Inc. | -12.77 Million USD | -1466.724% |